Cigarette smoking and subtypes of bladder cancer

International Journal of Cancer

Volumn 130, Issue 4, 2012, Pages 896-901

  Jiang, Xuejuan ^a   Castelao, J Esteban ^a,b   Yuan, Jian Min ^c   Stern, Mariana C ^a   Conti, David V ^a   Cortessis, Victoria K ^a   Pike, Malcolm C ^a,d   Gago Dominguez, Manuela ^a,e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^c UNIVERSITY OF MINNESOTA   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

bladder cancer; cigarette smoking; Los Angeles; nonsteroidal anti inflammatory drugs; tumor subtypes

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER INVASION; CANCER RISK; CANCER STAGING; CIGARETTE SMOKING; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; SEX DIFFERENCE; SUPERFICIAL CANCER; UNITED STATES;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RISK FACTORS; SEX CHARACTERISTICS; SMOKING; URINARY BLADDER NEOPLASMS;

EID: 83955165957     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26068     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Wu X-R,. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005; 5: 713-25. (Pubitemid 41486364)
3. Dalbagni G,. The management of superficial bladder cancer. Nat Clin Pract Urol 2007; 4: 254-60. (Pubitemid 46745486)
4. Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP,. Biology and management of bladder cancer. N Engl J Med 1990; 322: 1129-38. (Pubitemid 20149531)
5. Cutler SJ, Heney NM, Friedel GH,. Longitudinal study of patients with bladder cancer: factors associated with disease recurrence and progression. In:, Bonney WW, Prout GRJ, eds. Bladder cancer, vol. 1. Baltimore: Williams & Wilkins, 1982. 35-47.
6. Kaye KW, Lange PH,. Mode of presentation of invasive bladder cancer: reassessment of the problem. J Urol 1982; 128: 31-3. (Pubitemid 12048750)
7. Wolff EM, Liang G, Jones PA,. Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol 2005; 2: 502-10. (Pubitemid 41594404)
8. Cartwright RA, Adib R, Appleyard I, Glashan RW, Gray B, Hamilton-Stewart PA, Robinson M, Barham-Hall D,. Cigarette smoking and bladder cancer: an epidemiological inquiry in West Yorkshire. J Epidemiol Commun Health 1983; 37: 256-63. (Pubitemid 14200484)
9. Cartwright RA, Glashan RW, Gray B,. Survival of transitional cell carcinoma cases in 2 Yorkshire centres. Br J Urol 1980; 52: 497-9. (Pubitemid 11204026)
10. Glashan RW, Wijesinghe DP, Riley A,. The early changes in the development of bladder cancer in patients exposed to known industrial carcinogens. Br J Urol 1981; 53: 571-7. (Pubitemid 12251322)
11. Brooks DR, Geller AC, Chang J, Miller DR,. Occupation, smoking, and the risk of high-grade invasive bladder cancer in Missouri. Am J Ind Med 1992; 21: 699-713.
12. Hayes RB, Friedell GH, Zahm SH, Cole P,. Are the known bladder cancer risk-factors associated with more advanced bladder cancer? Cancer Causes Control 1993; 4: 157-62. (Pubitemid 23077023)
13. Thompson IM, Peek M, Rodriguez FR,. The impact of cigarette smoking on stage, grade and number of recurrences of transitional cell carcinoma of the bladder. J Urol 1987; 137: 401-3. (Pubitemid 17028264)
14. Castelao JE, Yuan JM, Skipper PL, Tannenbaum SR, Gago-Dominguez M, Crowder JS, Ross RK, Yu MC,. Gender- and smoking-related bladder cancer risk. J Natl Cancer Inst 2001; 93: 538-45. (Pubitemid 32318433)
15. Bernstein L, Ross RK,. Cancer in Los Angeles Countyed. Los Angeles, CA: University of Southern California, 1991.
16. Epstein JI, Amin MB, Reuter VR, Mostofi FK,. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22: 1435-48. (Pubitemid 28550639)
17. Guey LT, Garcia-Closas M, Murta-Nascimento C, Lloreta J, Palencia L, Kogevinas M, Rothman N, Vellalta G, Calle ML, Marenne G, Tardon A, Carrato A, et al,. Genetic susceptibility to distinct bladder cancer subphenotypes. Eur Urol 2010; 57: 283-92.
18. Sturgeon SR, Hartge P, Silverman DT, Kantor AF, Linehan WM, Lynch C, Hoover RN,. Associations between bladder cancer risk factors and tumor stage and grade at diagnosis. Epidemiology 1994; 5: 218-25. (Pubitemid 24073396)
19. Hinotsu S, Akaza H, Miki T, Fujimoto H, Shinohara N, Kikuchi E, Mizutani Y, Koga H, Okajima E, Okuyama A,. Bladder cancer develops 6 years earlier in current smokers: analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association. Int J Urol 2009; 16: 64-9.
20. Carpenter AA,. Clinical experience with transitional cell carcinoma of the bladder with special reference to smoking. J Urol 1989; 141: 527-8. (Pubitemid 19089141)
21. Jensen OM, Wahrendorf J, Blettner M, Knudsen JB, Sorensen BL,. The Copenhagen case-control study of bladder cancer: role of smoking in invasive and non-invasive bladder tumours. J Epidemiol Commun Health 1987; 41: 30-6. (Pubitemid 17017744)
22. Morrison AS, Proppe KH, Verhoek WG, Aoki K, Leck I, Ohno Y, Obata K,. Histologic features of bladder cancer in Boston. USA, Manchester, UK and Nagoya Japan. Int J Cancer 1982; 30: 701-5. (Pubitemid 13223561)
23. Raitanen MP, Nieminen P, Tammela TL,. Impact of tumour grade, stage, number and size, and smoking and sex, on survival in patients with transitional cell carcinoma of the bladder. Br J Urol 1995; 76: 470-4.
24. Knowles MA,. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 2006; 27: 361-73. (Pubitemid 43372866)
25. Zhang D, Okada S, Yu Y, Zheng P, Yamaguchi R, Kasai H,. Vitamin E inhibits apoptosis. DNA modification, and cancer incidence induced by iron-mediated peroxidation in. Wistar rat kidney. Cancer Res 1997; 57: 2410-4. (Pubitemid 27255899)
26. Hazra A, Grossman HB, Zhu Y, Luo S, Spitz MR, Wu X,. Benzo[a]pyrene diol epoxide-induced 9p21 aberrations associated with genetic predisposition to bladder cancer. Genes Chromosomes Cancer 2004; 41: 330-8. (Pubitemid 39488492)
27. Wallerand H, Bakkar AA, de Medina SGD, Pairon J-C, Yang Y-C, Vordos D, Bittard H, Fauconnet S, Kouyoumdjian J-C, Jaurand M-C, Zhang Z-F, Radvanyi F, et al., Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens. Carcinogenesis 2005; 26: 177-84. (Pubitemid 40207713)
28. Bakkar AA, Allory Y, Iwatsubo Y, de Medina SG, Maille P, Khreich N, Riou A, Leroy K, Vordos D, Abbou CC, Andujar P, Billebaud T, et al., Occupational exposure to polycyclic aromatic hydrocarbons influenced neither the frequency nor the spectrum of FGFR3 mutations in bladder urothelial carcinoma. Mol Carcinog 2010; 49: 25-31.
29. Pruthi RS, Derksen E, Gaston K, Wallen EM,. Rationale for use of cyclooxygenase-2 inhibitors in prevention and treatment of bladder cancer. Urology 2004; 64: 637-42. (Pubitemid 39446031)
30. Hass MA, Nichol P, Lee L, Levin RM,. Estrogen modulates permeability and prostaglandin levels in the rabbit urinary bladder. Prostaglandins Leukotrienes Essential Fatty Acids 2009; 80: 125-9.
31. Egan KM, Lawson JA, Fries S, Koller B, Rader DJ, Smyth EM, Fitzgerald GA,. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004; 306: 1954-7. (Pubitemid 39627863)
32. Wu WX, Ma XH, Zhang Q, Buchwalder L, Nathanielsz PW,. Regulation of prostaglandin endoperoxide H synthase 1 and 2 by estradiol and progesterone in nonpregnant ovine myometrium and endometrium in vivo. Endocrinology 1997; 138: 4005-12. (Pubitemid 27351957)